TY - JOUR
T1 - Cell-based protein delivery system for the inhibition of the growth of pancreatic cancer
T2 - NK4 gene-transduced oral mucosal epithelial cell sheet
AU - Manabe, Tatsuya
AU - Mizumoto, Kazuhiro
AU - Nagai, Eishi
AU - Matsumoto, Kunio
AU - Nakamura, Toshikazu
AU - Nukiwa, Toshihiro
AU - Tanaka, Masao
AU - Matsuda, Takehisa
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Purpose: Pancreatic resection for pancreatic cancer is the only curative modality, but the high incidence of local recurrence after surgery results in a very poor prognosis. This study aims to develop a new therapeutic tool that could inhibit the growth of remnant cancer cells, which is based on local delivery of NK4 (hepatocyte growth factor antagonist) secreted from an NK4 gene-transduced oral mucosal epithelial cell (OMEC) sheet (NK4-sheet), which is adhered to the resected surface. Experimental design: OMECs, harvested and cultured according to 3T3 feeder layer technique, were seeded on a collagen mesh-overlayered, biodegradable VICRYL mesh to produce an OMEC sheet. NK4 gene transduction was mediated by recombinant adenovirus (Ad-NK4). Applicability of OMECs for cell-based NK4 delivery was examined. An experimental model using nude mice was established to determine the effect of an NK4-sheet on both tumor growth and angiogenesis. Results: NK4 secreted from Ad-NK4-transduced OMECs suppressed MRC-5-induced invasion of pancreatic cancer cell lines. Heterotopically implanted gene-transduced OMECs remained for ≥10 days while gradually decreasing. NK4-sheets inhibited both angiogenesis and tumor growth in vivo. Conclusion: Autologous OMEC was found to be suited to this purpose because of no secretion of hepatocyte growth factor, ease in harvesting from a patient, reasonably high proliferation potential, and no immune reaction. Although NK4-sheets under development exhibited a low level and short period of NK4 secretion, it is expected that this system may have a great potentiality of protein delivery system to target tissue at clinical situations when it is loaded with multilayered OMECs.
AB - Purpose: Pancreatic resection for pancreatic cancer is the only curative modality, but the high incidence of local recurrence after surgery results in a very poor prognosis. This study aims to develop a new therapeutic tool that could inhibit the growth of remnant cancer cells, which is based on local delivery of NK4 (hepatocyte growth factor antagonist) secreted from an NK4 gene-transduced oral mucosal epithelial cell (OMEC) sheet (NK4-sheet), which is adhered to the resected surface. Experimental design: OMECs, harvested and cultured according to 3T3 feeder layer technique, were seeded on a collagen mesh-overlayered, biodegradable VICRYL mesh to produce an OMEC sheet. NK4 gene transduction was mediated by recombinant adenovirus (Ad-NK4). Applicability of OMECs for cell-based NK4 delivery was examined. An experimental model using nude mice was established to determine the effect of an NK4-sheet on both tumor growth and angiogenesis. Results: NK4 secreted from Ad-NK4-transduced OMECs suppressed MRC-5-induced invasion of pancreatic cancer cell lines. Heterotopically implanted gene-transduced OMECs remained for ≥10 days while gradually decreasing. NK4-sheets inhibited both angiogenesis and tumor growth in vivo. Conclusion: Autologous OMEC was found to be suited to this purpose because of no secretion of hepatocyte growth factor, ease in harvesting from a patient, reasonably high proliferation potential, and no immune reaction. Although NK4-sheets under development exhibited a low level and short period of NK4 secretion, it is expected that this system may have a great potentiality of protein delivery system to target tissue at clinical situations when it is loaded with multilayered OMECs.
UR - http://www.scopus.com/inward/record.url?scp=0041524002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041524002&partnerID=8YFLogxK
M3 - Article
C2 - 12912968
AN - SCOPUS:0041524002
SN - 1078-0432
VL - 9
SP - 3158
EP - 3166
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -